Reducing or inhibiting ocular damage by hyaluronidase administration
AssigneeMed Progress, LLC
InventorSteve Yoelin
Life of this patent
Estimating the term…
Abstract
The present disclosure discloses compositions comprising a hyaluronidase, devices comprising such compositions, as well as methods and uses employing such compositions and devices to reduce or eliminate a hyaluronic acid-induced blockage of one or more blood vessels supplying an eye of an individual; methods and uses for employing such compositions and devices to reduce or inhibit a vascular occlusion in an eye of an individual; and methods and uses for employing such compositions and devices to reduce or inhibit a hyaluronic acid-induced loss of vision of an individual.
Claims20
A method of reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye in an individual in need thereof, the method comprising administering at most 500 μL of a composition comprising a therapeutically effective amount of hyaluronidase of at least 2,000 IU/mL to a suprachoroidal space of the eye of the individual,
- wherein administration of the hyaluronidase reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye in at most 30 minutes, thereby restoring or maintaining normal retinal blood flow.
A method of reducing or inhibiting a vascular occlusion in an eye of an individual in need thereof, the method comprising administering at most 400 μL of a composition comprising a therapeutically effective amount of hyaluronidase at least 3,000 IU/mL to a suprachoroidal space of the eye of the individual,
- wherein administration of the hyaluronidase reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye in at most 30 minutes, thereby restoring or maintaining normal retinal blood flow.
Dependencies are inferred from the claim text.